Ceribell, Inc.
Business
Ceribell is a medical technology company that develops the Ceribell System, a point-of-care EEG platform for rapid diagnosis and continuous monitoring of seizures and other neurological conditions in acute care settings. The system combines portable hardware (disposable headbands/headcaps and pocket-sized recorders) with AI-powered algorithms called Clarity to enable bedside seizure detection and monitoring. Ceribell generates recurring revenue from disposable wearable sales and monthly subscription fees for cloud-based portal access, clarity algorithms, and recorders, serving over 600 U.S. hospitals.
Summary from 10-K filed 2026-02-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | 89 | 65 | 45 | |
| Total cost of revenue | 11 | 9 | 7 | |
| Gross profit | 78 | 57 | 38 | |
| Research and development | 19 | 14 | 9 | |
| Sales and marketing | 73 | 49 | 39 | |
| General and administrative | 44 | 34 | 20 | |
| Total operating expenses | 137 | 96 | 68 | |
| Loss from operations | −58 | −40 | −30 | |
| Interest expense | −2 | −2 | −2 | |
| Change in fair value of warrant liability | 0 | −1 | 48,000 | |
| Other income, net | 7 | 3 | 3 | |
| Loss, before provision for income taxes | −53 | −40 | −29 | |
| Provision for income tax expense | 0 | 0 | −11,000 | |
| Net loss | −53 | −40 | −29 | |
| Basic (per share) | −1.46 | −3.39 | −5.56 | |
| Diluted (per share) | −1.46 | −3.39 | −5.56 | |
| Basic (shares) | 37 | 12 | 5 | |
| Diluted (shares) | 37 | 12 | 5 | |
| Unrealized gain on marketable securities | 159,000 | 0 | — | |
| Comprehensive loss | −53 | −40 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 40 | 194 | 34 | — | |
| Marketable securities | 119 | — | — | — | |
| Accounts receivable, net | 15 | 11 | 8 | — | |
| Inventory | 7 | 7 | 6 | — | |
| Contract costs, current | 2 | 2 | 2 | — | |
| Prepaid expenses and other current assets | 3 | 3 | 2 | — | |
| Total current assets | 187 | 217 | 52 | — | |
| Property and equipment, net | 2 | 2 | 2 | — | |
| Operating lease right-of-use assets | 2 | 2 | 2 | — | |
| Contract costs, long-term | 2 | 2 | 1 | — | |
| Other non-current assets | 3 | 2 | 2 | — | |
| Total assets | 196 | 225 | 59 | — | |
| Accounts payable | 3 | 1 | 732,000 | — | |
| Accrued liabilities | 14 | 10 | 8 | — | |
| Contract liabilities, current | 101,000 | 97,000 | 206,000 | — | |
| Operating lease liability, current | 1 | 1 | 694,000 | — | |
| Other current liabilities | 818,000 | 609,000 | 595,000 | — | |
| Total current liabilities | 19 | 13 | 22 | — | |
| Notes payable, long-term | 20 | 20 | — | — | |
| Contract liabilities, long-term | 0 | 30,000 | 44,000 | — | |
| Other liabilities, long-term | 106,000 | 356,000 | 441,000 | — | |
| Operating lease liability, long-term | 1 | 1 | 2 | — | |
| Total long-term liabilities | 21 | 21 | 2 | — | |
| Total liabilities | 40 | 34 | 24 | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | |
| Preferred stock, $0.001 par value; Authorized shares: 10,000,000 as of December 31, 2025 and December 31, 2024, respectively Issued and outstanding shares: none as of December 31, 2025 and December 31, 2024, respectively | — | — | — | — | |
| Common stock, $0.001 par value; Authorized shares: 500,000,000 as of December 31, 2025 and December 31, 2024, respectively Issued and outstanding shares: 37,485,124 and 35,850,60 as of December 31, 2025 and December 31, 2024, respectively. | 38,000 | 36,000 | 5,000 | — | |
| Additional paid-in capital | 375 | 358 | 14 | — | |
| Accumulated other comprehensive income | 159,000 | — | — | — | |
| Accumulated deficit | −220 | −167 | −127 | — | |
| Total stockholders' deficit | 155 | 191 | −112 | −86 | |
| Total liabilities and stockholders' equity | 196 | 225 | 59 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net loss | −53 | −40 | −29 | |
| Depreciation and amortization expense | 1 | 1 | 847,000 | |
| Noncash lease expense | −101,000 | 59,000 | −19,000 | |
| Stock-based compensation expense | 12 | 5 | 3 | |
| Amortization of debt discount and accretion of premium on term loans | 415,000 | 382,000 | 363,000 | |
| Accretion (amortization) of discount and premium on marketable securities | −2 | 0 | — | |
| Loss on disposal of property and equipment and recorders | 104,000 | 95,000 | 181,000 | |
| Accounts receivable, net | −4 | −3 | −3 | |
| Inventory | −351,000 | −1 | −2 | |
| Prepaid expenses and other current assets | 345,000 | −1 | −965,000 | |
| Contract costs | −713,000 | −591,000 | −773,000 | |
| Other non-current asset | −415,000 | −65,000 | 113,000 | |
| Accounts payable | 2 | 250,000 | 309,000 | |
| Accrued liabilities and other current liabilities | 4 | 2 | 2 | |
| Contract liabilities | −26,000 | −123,000 | −93,000 | |
| Net cash used in operating activities | −41 | −35 | −29 | |
| Purchases of recorder components and recorders | −755,000 | −258,000 | −780,000 | |
| Purchases of property and equipment | −767,000 | −1 | −983,000 | |
| Purchases of marketable securities | −211 | 0 | — | |
| Proceeds from maturities of marketable securities | 94 | 0 | — | |
| Net cash used in investing activities | −118 | −2 | −2 | |
| Proceeds related to employee stock plans | 5 | 1 | — | |
| Taxes withheld and paid related to settlement or vesting of equity awards | −236,000 | 0 | — | |
| Proceeds from debt issuance | 0 | 8 | — | |
| Debt issuance cost | −150,000 | −304,000 | — | |
| Payment of deferred IPO offering costs | 0 | −5 | — | |
| Proceeds from IPO, net of commissions | 0 | 193 | — | |
| Net cash provided by financing activities | 5 | 197 | −3 | |
| Net increase (decrease) in cash and cash equivalents | −154 | 160 | −34 | |
| Cash paid for interest | 2 | 2 | 2 | |
| Right-of-use asset obtained in exchange for operating lease obligation | 1 | 778,000 | — | |
| Property and equipment included in accounts payable and accrued expenses | 63,000 | 99,000 | — | |
| Recorder components included in accounts payable and accrued expenses | 67,000 | 69,000 | — | |
| Conversion of redeemable convertible preferred stock into common stock on completion of IPO | 0 | 147 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Ceribell, Inc.'s CIK number?
Ceribell, Inc.'s SEC CIK number is 0001861107 (1861107). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Ceribell, Inc.'s SEC filings?
All of Ceribell, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Ceribell, Inc. last report earnings?
Ceribell, Inc. (CBLL) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216821). This is Ceribell, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Ceribell, Inc.'s most recent earnings 8-K?
Ceribell, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216821. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Ceribell, Inc.'s latest earnings 8-K →
Look up any company's CIK number →